XTX Topco’s Sage Therapeutics SAGE Stock Holding History

XTX Topco’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,698	Closed	–	–	3726
2025 Q3	$0	Buy	29,698 +16,620	+127%	+$150K	﹤0.01%	3171
2025 Q2	$119K	Sell	13,078 -28,973	-69%	-$213K	﹤0.01%	1843
2025 Q1	$334K	Buy	+42,051	New	+$308K	0.02%	1320
2024 Q3	–	Sell	-48,249	Closed	-$524K	–	2536
2024 Q2	$524K	Buy	+48,249	New	+$618K	0.04%	636
2023 Q4	–	Sell	-38,093	Closed	-$784K	–	2059
2023 Q3	$784K	Buy	38,093 +31,258	+457%	+$903K	0.13%	181
2023 Q2	$321K	Buy	6,835 +1,847	+37%	+$91.9K	0.06%	670
2023 Q1	$209K	Buy	+4,988	New	+$214K	0.04%	928
2021 Q4	–	Sell	-5,991	Closed	-$265K	–	963
2021 Q3	$265K	Buy	5,991 +228	+4%	+$10.5K	0.09%	384
2021 Q2	$327K	Buy	+5,763	New	+$407K	0.11%	330

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

XTX Topco's SAGE Position: Q4 2025 in Review

XTX Topco sold out of Sage Therapeutics (SAGE) in Q4 2025, closing a stake of 29,698 shares.

XTX Topco first reported a position in SAGE in Q2 2021 and held it in 9 quarters. The position peaked at $784K in Q3 2023. 2 funds tracked by Wall St. Rank hold SAGE as of Q4 2025.

XTX Topco reported no remaining Sage Therapeutics position as of Q4 2025 after selling out during the quarter.
XTX Topco sold 29,698 Sage Therapeutics shares in Q4 2025.
XTX Topco first reported a position in Sage Therapeutics in Q2 2021 and held it in 9 quarters.
XTX Topco's Sage Therapeutics position peaked at $784K in Q3 2023.
2 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.